Introduction
Of the many patients with psychological illness or disorders in which emotional factors are important, a large proportion are given psychotropic drugs. Many improve because of this treatment and some despite it. The potent agents now available are liable to produce side-effects or toxic effects which have to be set against the potential benefits conferred by these drugs. If drug treatment is appropriate the problem is to choose the compound most liable to produce beneficial effects-regardless of whether weightfor-weight it is the most potent drug-which also has the least risk of unwanted effects (Lader, 1967) . This is clearly a complex matter and to gather sufficient information to make a reasonable choice requires both adequate trials to demonstrate the drug's clinical efficacy and sufficient clinical experience to discover the incidence and nature of the side-effects. In clinical trials of psychotropic drugs all the problems of spontaneous change, the effect of concurrent environmental changes, the patient's relationship to medical staff, the potential bias of patient and doctor, the difficulty of assessing subjective changes and of measuring relevant objective changes, demand a careful design to the trial if the results are to have any significance. It is also necessary to verify that the subjects are taking the medication under trial, for it has ,been touid that among out-patients as many as 48% may not be taking the treatment prescribed (Wilcox, Gillan & Hare, 1965) .
Many doctors have pointed out that in their hands various psychotropic drugs prove to be more successful than results published even in satisfactorily controlled trials. Although this may be partially accounted for by their better intuitive selection of appropriate patients for particular treatments, it may well be that faith plays a large part. Faith may well move mountains, and enthusiastic approach can help certain patients who have had no benefit from the treatment of more cautious therapists. Unfortunately, when it comes to proving that faith has actually moved the mountain, the peak often remains obstinately far away unless the distance is assessed by the fervent practitioner free to move about in the haze appropriate to the altitude. In these circumstances, clinical enthusiasm is an unreliable basis for pharmacological knowledge or subsequent hypothesis.
Periodic reviews of the toxicity of psychotropic drugs report unwanted side-effects, e.g. over-sedation, hypotension, or extra-pyramidal disorders, dangerous allergic responses, e.g. agranulocytosis, and toxic effects, e.g. liver necrosis or acute hypertension (Hollister, 1964) . There are also the dangers of addiction and overdose. In any one year in Great Britain, each of the more popular drugs used in the treatment of anxiety, depression or schizophrenia is quite likely to feature in at least a million prescriptions. Even if the dangers are relatively infrequent, there are bound to be a number of occasions when drug toxicity will cause a patient (or the relatives) and the doctor to doubt if the original prescription was really justified. This clearly means that even familar drugs should not be prescribed without due consideration and to do so is to incur an unjustifiable risk. Moreover (Mcllwain, 1966) . In electrophysiological work, the brain-stem reticular system has shown itself to be particularly sensitive to barbiturate action, although its effect is by no means limited to this (Brazier, 1965) . The relationship between these metabolic and electrophysiological changes and the reduction of anxiety is still far from clear, although there may be some connection between the level of arousal in terms of brain activity and the features of anxiety.
Owing to some of their disadvantages the barbiturates are no longer such an automatic first choice to sedate anxious patients-there is also a swing of opinion due to a discontent that leads to the use of other sedatives, not because they are better, but because they are different. The disadvantages of barbiturates include drug dependency, where repeated ingestion results in tolerance, reduced therapeutic benefit and social problems. Not a few patients, often those with some inadequacy of personality, find it very difficult to stop taking the drug once it has provided partial relief from chronic emotional distress. More serious addiction is not rare, patients demonstrating an impairment of concentration, co-ordination or consciousness from time to time. Barbiturate withdrawal is liable to cause an anxiety state, fits or delirium on withdrawal not unlike that other sedative, alcohol (Isbell & Frazer, 1950) . The problem more frequently encountered in hospital is the acute intoxication from an overdose, often taken impulsively by desperate people who can find no solution to their problems (Kessel, 1965) . A large majority of such patients recover consciousness with conservative treatment, although further measures may assist drug excretion in the seriously intoxicated person (Geall, 1966 (Jenner, 1965k One comparative trial of chlordiazepoxide and amylobarbitone sodium with a placebo was of particular interest in that it showed the value of both drugs for anxious patients but could show no significant difference between them when using a number of physiological and clinical measures (Lader & Wing, 1965) . Tranquillizers Phenothiazines Chlorpromazine soon made its mark when introduced into psychiatry in the early 1950s. It was clear that the phenothiazines held thera-peutic promise because of the actions of compounds such as promethazine which was not only an antihistamine, but also a sedative and had the power of potentiating anaesthetics. Chlorpromazine was also found to have many actions and these included the property of Icalming anxious or agitated people. Its ability to do this without necessarily altering the level of consciousness to any great extent led to its recognition as a very valuable clinical 'tranquillizer'.
This desirable achievement aroused great pharmacological curiosity which has not yet been assuaged by an adequate explanation. There is evidence that chlorpromazine influences a number of enzyme systems including interfering with oxidative phosphorylation (Richter, 1965) but the link between its metabolic effects and clinical action is obscure. Chlorpromazine antagonizes adrenaline in various animal experiments and, to some extent, it also opposes the action of acetylcholine, histamine and serotonin. Quite possibly its antagonism to biogenic amines in the brain accounts for some of its depressant actions. Its depressant effect would be expected to be more selective than ordinary sedatives, and this is confirmed as regards the brain-stem reticular system. Electrophysiological work shows differences between chlorpromazine action at this level and that of the barbiturates which produce a marked general reduction of the responsiveness of the brain-stem arousal system. Chlorpromazine depresses the reticular system sensory input which comes through collateral branches from the main afferent pathways, but this drug does not greatly alter the responsiveness of the reticular system to direct electrical stimuli. Chlorpromazine given to cats in doses that do not produce general sedation will potentiate normal habituation, i.e. reduce responsiveness to arousal responses and to conditioned stimuli, whereas in experiments without chlorpromazine the conditioned responses habituate more slowly. This effect of enhancing habituation to conditioned stimuli may well have intriguing links with the drug's clinical tranquillizing action (Bradley, 1963) . With chlorpromazine's success a number of other phenothiazines followed. The basic phenothiazine structure is shown in Fig. 1 , with substitutions at the R1 and R2 positions. The R2 substitutions are simpler, often a halogen, methyl or methoxy group, which affects the potency of the compound. Common substitutions at the R1 group are dimethylamine, piperazine and piperidine side-chains and these three types form convenient groups for clinical consideration. Examples are shown in Fig. 1 .
The clinical actions of the dimethylamine group are typified by chlorpromazine, still a very popular drug. It has now been amply proved that this drug can bring about a great improvement in patients with acute schizophrenia. One study of 400 acutely ill patients showed that 75% of those taking phenothiazines, including chlorpromazine, showed marked or moderate improvement in 6 weeks compared with only 23% of those receiving an inert preparation (N.I.M.H. Group, 1964) . Although 'tranquillizers', chlorpromazine and similar compounds in larger doses will sedate and cause drowsiness. This impairment of consciousness is much less than that brought about by therapeutically equivalent doses of barbiturates and so chlorpromazine is often useful in restless patients who are confused or suffering from withdrawal of addictive drugs. It also has its uses in anxious patients. Having so many actions chlorpromazine is bound to have side-effects, some of which are disadvantageous. These include drowsiness, hypotension and Parkinsonism. Until recently it was confidently stated that the extra-pyramidal sideeffects were temporary phenomena which would vanish when the dose of phenothiazines was reduced or stopped; but now a few cases have been reported of persistent abnormal movements of face, tongue and jaw following prolonged phenothiazine treatment (Hunter, Earl & Janz, 1964) .
Chlorpromazine can produce idiosyncratic toxic effects in some patients. At one time it appeared that jaundice might occur so frequently as to seriously limit the value of the drug, but its incidence is not so high as to prohibit the use of this compound. When jaundice does occur it is of a cholestatic type with the clinical and biochemical picture of obstructive jaundice, but without any signs of extra-hepatic obstruction, of course; it can easily prove a diagnostic pitfall. Fortunately this condition is usually benign (Cook & Sherlock, 1965) . Idiosyncratic responses include skin eruptions and some individuals become exceedingly sensitive to the drug, often exhibiting a photosensitivity as well. The prolonged taking of phenothiazines for 2 or 3 years can produce deposits in the lens, cornea and the skin (Mathalone, 1965) , and although no serious ill-effects are apparent the question has been raised whether widespread tissue deposits of a phenothiazine metabolite may do more than discolour skin. Occasional sudden deaths have occurred in patients receiving phenothiazines and it has been suggested that the drug could affect the tissues of the heart (Lancet, 1965 (Post, 1966 (Hughes & Little, 1967 The use of lithium carbonate for manic illness was first suggested in 1949 but it did not become widely used because of its dangers and the difficulties of proving its value in a variable illness like mania. Serious risks, especially to the kidney, were encountered more when lithium was used as a sodium substitute (Schou, 1957) . In psychiatric practice drowsiness, tremor and ataxia are warning signs of lithium intoxication and it is as well to keep the serum lithium level below 2 mEq/l. With such a regime mania is often controlled (Maggs, 1963) . It has also been claimed that lithium improves depression and may relieve the recurrent mood-swings of manicdepressive psychosis.
In view of the changes in body sodium that have been described in affective disorders, the influence of lithium in this respect has aroused considerable interest. Using radioactive isotopes, Coppen and his co-workers (1965) reported that the residual sodium (intracellular and exchangeable bone sodium) fell when patients recovered from depression; similar changes appeared to occur in mania. It seemed from one investigation that giving lithium to such patients increased the exchangeable sodium, probably at the expanse of the residual sodium, but a recent study has failed to confirm this (Coppen & Shaw, 1967) .
Anti-depressants
Although sedatives, notably alcohol, with their central nervous system depressant action, can give rise to euphoria, it is only in the last few years that some drugs have been used because they specifically relieve depressions of mood. Sedatives and tranquillizers relieve anxiety and agitation in depressive conditions but do not appear to have as great an effect on the depressive symptoms, although there is evidence that some of the phenothiazines such as thioridazine or perphenazine may have a mild anti-depressant action (Overall et al., 1964; Hinton, 1959 The first drug of this group observed to have an anti-depressant action was iproniazid (Marsilid) when it induced euphoria in some patients in whom it was tried as a treatment for tuberculosis. Although iproniazid did not prove to be as successful as isoniazid against the infection, it continued to be used for its psychotropic action and is not without its advocates today. The empiric use of the drug was soon linked with its action of inhibiting MAO. Iproniazid was found to increase the brain serotonin (5-hydroxytryptamine) in some animals. This seemed to provide a neat contrast with reserpine which depletes the stores of serotonin in the brain, depresses activity in animals and can sometimes depress the mood of man to a suicidal level. Moreover, there is some evidence that in the treatment of depressed patients giving trypto-phan, a precursor of serotonin, can potentiate the therapeutic action of MAO inhibitors (Coppen, Shaw & Farrell, 1963 (Pletscher, 1966 ). It has even been possible to measure the 5-hydroxytryptamine content in the brain stem of patients who have died while taking MAO inhibitors and the serotonin level has been found to rise after 2 weeks of such treatment (Maclean et al., 1965) .
As would be expected, the discovery of a drug that could relieve depression in a novel way was shortly followed by a number of similar compounds, accompanied by reports of toxic effects and second thoughts about the therapeutic efficacy of the various compounds. Many of this group, for example, phenelzine (Nardil), nialamide (Niamid) and isocarboxazid (Marplan), like iproniazid, contained the N:N bond of hydrazine. The hydrazine MAO inhibitors are liable to produce hypotension and other sideeffects, but more serious is the liver damage they occasionally inflict, isoniazid having the worst reputation for this. This toxic effect results in a condition which resembles virus hepatitis histologically and clinically; it can be fulminant and its mortality rate, once jaundice develops, has been reported to be as high as 25% (Cook & Sherlock, 1965 (Sargant & Dally, 1962) Evidence has been gathered that these hypertensive episodes are largely due to monoamines in the diet which, owing to the very effective inhibition of MAO by tranylcypromine, are absorbed into the bloodstream and not metabolized in the usual fashion (Blackwell et al., 1967) . The significant monoamines are tyramine which is found in some cheeses, yeast extract and some alcoholic drinks, histamine which is found in yeast extract, and dopa which is present in broad beans. These can all cause unpleasant or dangerous effects. Since this knowledge became available in 1963, patients taking MAO inhibitors, particularly tranylcypromine, should have been warned to avoid these particular items in their diet. In one enquiry this simple measure proved sufficiently effective to reduce the incidence of hypertensive crises in patients taking MAO inhibitors from 8-4% to 33%, and most of the 3-3 % had disregarded the warning (Bethune et al., 1964 (Atkinson & Ditman, 1965) .
Tricyclic compounds
At about the same time that the MAO inhibitors were introduced into psychiatric practice, imipramine was also being prescribed as an antidepressant. Its iminodibenzyl structure is very similar to the phenothiazines, with a CH2-CH2 group in place of the S atom (see Fig. 3 ). Animal work had originally suggested that its clinical use would be as a tranquillizer but Kuhn (1958) observed that patients were often relieved of their depressive symptoms. Following the success of this compound as an anti-depressant there have been further modifications in the central structure to produce other tricyclic compounds and, of course, the side chain has also had its modifications. The structures of one or two frequently-used derivatives are shown in Fig. 3 .
Explanations have been advanced to explain the anti-depressant effect of imipramine in terms of its pharmacological action on the monoamines in the brain. In animals imipramine can prolong the action of noradrenaline (Holtz & Westermann, 1965 ). Imipramine does not inhibit MAO, however, and does not alter the level of brain amines. It has been suggested that the drug interferes with the normal rebinding and inactivation of noradrenaline when released at the nerve endings. Imipramine may alter the membrane permeability at this site, increasing the activity of noradrenaline at the receptor site . In animal experiments it has been shown that imipramine is metabolized and, by losing a methyl group, becomes desipramine (see Fig. 3 ) an active agent. Given to rats desipramine sensitizes the adrenergic receptors to the action of brain catecholamines especially when they are released by reserpine-like substances (Brodie, 1965) . Such theories regarding the pharmacological relief of depression in man, however, must remain speculative as long as the relevant metabolic accompaniments of lowered mood are not established. Owing to their lower toxicity and greater therapeutic efficacy the tricyclic anti-depressants are usually prescribed more readily than the MAO inhibitors. Serious toxic sequelae are uncommon, although the side-effects of these drugs can occasionally be so troublesome as to limit their use. The disturbance of the autonomic system induced by these drugs can cause patients to experience dryness of the mouth, increased sweating, disturbed accommodation, constipation and dysuria. Tremor, unsteadiness, alterations in cardiac rate or rhythm and hypotension also occur. As the pharmacological actions of these drugs would lead one to expect, giving them concurrently with a MAO inhibitor could possibly lead to an excessive brain stimulation, resulting in tremors, sweating, vascular collapse and hyperpyrexia. Nevertheless, a few physicians make a practice of using the MAO inhibitors and tricyclic anti-depressants together in a powerful pharmacological brew, which they justify on the grounds that depressive illness itself endangers life and that the theoretical risks of the treatment are rarely encountered in practice. The tricyclic compounds are not hepatotoxic in the manner of hydrazine MAO inhibitors; cholestatic jaundice and agranulocytosis, which occur with the related phenothiazines, are uncommon sequelae to treatment with tricyclic antidepressants.
There is greater conviction about the relief of depression by the tricyclic compounds than MAO inhibitors. The majority of controlled trials ha* shown a significant difference from placebo although a few have not. Anti-depressant agents have to bear comparison with electroconvulsive therapy (ECT) an accepted effective treatment for severely depressed patients, but a treatment that requires a skilled team to avoid any unnecessary anaesthetic or other risks, and even when well administered may prove an unpleasant procedure for some patients besides giving some a temporary memory disturbance. The early controlled studies of imipramine by Kiloh and Ball (Ball & Kiloh, 1959; Kiloh & Ball, 1961) showed its effectiveness and indicated that although depression might not be relieved so promptly with the drug as with ECT, continued treatment-with imipramine could reduce the chances of relapse. These findings are similar to the careful M.R.C. trial of treatments for depression (1965) . It is generally held that an adequate dose of imipramine of 150-200 mg daily may take 1-3 weeks before the therapeutic effect becomes apparent. In the M.R.C. trial, after 4 weeks' treatment 39 % of those on the placebo had lost all symptoms (emphasizing the need for controls in such experiments) while 52% on imipramine and 71 % receiving ECT were well. On being followed up 6 months later, the difference in the outcome between patients treated with imipramine and ECT had gone, both treatments resulted in a little over half the patients remaining well.
This trial also indicated that imipramine is more effective in men than women. When attempts are made to find particular forms of depression responsive to particular anti-depressants, the evidence is contradictory; this is only to be expected while it is quite unclear if there are separable forms of depressive illness. It is often said that imipramine relieves 'endogenous' depression more often than 'reactive' depression but in addition to the difficulties of distinguishing the types this comparison is not as simple as it sounds; if, for instance, the circumstances to which a person is reacting persist. it will make it difficult for any drug to produce a contented mind. Attempts to relate clinical features of the illness to a favourable outcome with imipramine have often been disappointing (Fleminger & Groden, 1962) . A report from the United States showed that some depressed patients with anxious or phobic features responded well to imipramine (Klein, 1964) whereas this seems very like the group of patients which some workers in Britain say responds particularly well to MAO inhibitors. Attempts have been made to distinguish those responding to MAO inhibitors from those responding to tricyclic compounds and relating this to genetic aspects of the individual (Pare, Rees & Sainsbury, 1962) . Although this approach holds greater theoretical promise than the disappointing attempts to delineate syndromes of depression susceptible to particular drugs, the results are as yet inconclusive.
Other related compounds now compete with imipramine as the anti-depressant drug of choice. With the discovery of the part played by desipramine as an active agent in rats given reserpine, it was hoped that using desipramine (Pertofran) might shorten the period taken by imipramine before the effects of treatment became apparent. Unfortunately this hope has not been borne out to any clinically significant extent, and in depressed people imipramine seems to be the more useful drug (Edwards, 1965) . A slight change in the central structure of imipramine has produced amitriptyline (see Fig. 3 ), a compound which has proved to be of considerable clinical value. Controlled trials by Hordern and fellow workers (Burt et al., 1962; Hordern et al., 1964 ) have compared amitriptyline and imipramine, and shown the former to be better in some respects. Other comparative trials of amitriptyline have also found it equal or superior to imipramine (Hoenig & Visram, 1964) .
Amitriptyline is similar in therapeutic effect and side-effects to imipramine. It is more likely to make patients drowsy, but this is sometimes an asset in patients with depressive agitation or insomnia-imipramine can worsen insomnia. Hordern, reviewing the treatment of depression (1965) (Robinson et al., 1963) .
The use of psychotomimetic drugs, be they LSD, mescaline, psilocybin, psilocyn, N,N'-dimethyltryptamine (DMT) or other compounds, is not without complications. There are the social issues involved in repeated resort to the drugs, and the occasional adverse psychological responses to the drugs such as a prolonged mental disturbance or an acute distress which has led to suicide (Faillace, 1966) . Recently some evidence has been discovered to show that LSD and related drugs may alter chromosomal structure, a potentially sinister finding (Lancet, 1967) .
The fact that drugs can produce abnormal mental states which have some resemblances to schizophrenia has prompted a number of theories about the nature of their pharmacological action and the aetiology of mental illness. Some of these drugs have a resemblance to normally occurring catecholamines and serotonin; mescaline, for instance has a similar basic structure to noradrenaline (see Fig. 4 ). Perhaps a disturbance of a metabolic process such as methylation could cause a biochemical upset manifested by psychological changes. In the past few years the significance of various toxic or abnormal substances which have been described as present in the serum or urine of schizophrenic patients has been widely debated and currently the role of dimethoxyphenylethylamine and the 'pink spot' have been discussed and disputed (Smythies, 1967) . As yet none of the reports of abnormal metabolities described as occurring in schizophrenics have been wholly accepted but in spite of past disappointments the promise remains. 
Conclusion
The available knowledge concerning psychotropic drugs is now vast, but very far from complete. Assumptions and inadequate data lead to fashions of treatment many of which may, in retrospect, prove hard to justify. In the absence of a satisfactory understanding of the action of psychotropic drugs, it is not easy to fit new knowledge into a unifying pattern nor to summarize the present position. A chapter on recent advances in this field, which contained 951 references, included the comment that we now need reviews of reviews (Siminoff, 1964) . The present review is brief, patchy, presumably biassed and bound to be out of date in several respects. This warning is meant to convey an implied apology, together with an appreciation of the continuing growth of pharmacological and therapeutic knowledge on which one aspect of psychiatric treatment is based.
